Seelos Therapeutics Inc. (SEEL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Seelos Therapeutics Inc. (SEEL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.37

-0.17 (-31.49%)

At close: Nov 18, 2024, 8:58 PM

undefined% (undefined)

Bid	n/a
Market Cap	214.97K
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	351.04
PE Ratio (ttm)	0
Forward PE	n/a
Analyst	Hold

Ask	n/a
Volume	28,919
Avg. Volume (20D)	484,474
Open	0.45
Previous Close	0.54
Day's Range	0.20 - 0.45
52-Week Range	0.20 - 614.40
Beta	undefined

About SEEL

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotroph...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 19, 1999

Employees 8

Stock Exchange NASDAQ

Ticker Symbol SEEL

Website https://seelostherapeutics.com

Analyst Forecast

According to 1 analyst ratings, the average rating for SEEL stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

News

6 months ago · investorplace.com

3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers

Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketam...

1 year ago · investorplace.com

Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution

Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine...

1 year ago · investorplace.com

Why Are Stocks Up Today?

Stocks are up today as investors react to the latest comments from members of the Federal Reserve. The most important of these comes from Fed Governor Christopher Waller.

1 year ago · investorplace.com

Why Is Seelos Therapeutics (SEEL) Stock Down 42% Today?

Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Wednesday after the clinical-stage biopharmaceutical company priced a public offering of its shares. That public offering has Seelos Therapeutic...

1 year ago · pennystocks.com

Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List

Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 1...

1 year ago · pennystocks.com

Best Penny Stocks This Week? 3 To Watch During Earnings Season

The process of buying penny stocks is similar to purchasing any other stock shares. The main difference is penny stocks are often not listed on major exchanges like the NYSE and Nasdaq.

1 year ago · businesswire.com

Empery Alleges Critical Clinical Trial Misrepresentations by Seelos Therapeutics

NEW YORK--(BUSINESS WIRE)--Empery Asset Management, LP (“Empery”) wishes to inform shareholders of Seelos Therapeutics, Inc (the “Company” or “Seelos”) that Empery transmitted a letter to management a...

1 year ago · investorplace.com

Why Is Seelos Therapeutics (SEEL) Stock Down 25% Today?

Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Thursday after the company released results from a clinical trial. Seelos Therapeutics first reported results from its Phase 2 trial of SLS-002 ...

1 year ago · proactiveinvestors.com

Seelos tumbles 66% as depression drug fails after it recruits too few patients

Seelos Therapeutics (NASDAQ:SEEL) Inc's share price plummeted by 66% pre-market after the company announced that its phase II study for SLS-002, a treatment for adults with major depressive disorder a...

1 year ago · marketwatch.com

Seelos Therapeutics' stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpoint

Seelos Therapeutics Inc.'s stock SEEL tumbled 36% in premarket trade Wednesday, after the company reported promising results from a trial of a treatment for Acute Suicidal Ideation and Behavior (ASIB)...

1 year ago · investorplace.com

7 Biotech Stocks to Sell in September Before They Crash & Burn

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

1 year ago · seekingalpha.com

Seelos: 2 Catalysts Before End Of 2023 Make This A Must Watch

Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideation and behavior for MDD, are expected to be released by Q3 of 2023. The major depressive disorder...

2 years ago · seekingalpha.com

Scrutinizing Psychedelic Stocks

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.